Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum

Bayer Pharma Aktiengesellschaft

Deutsches Krebsforschungszentrum Heidelberg

Rienk Offringa

Ulf Bömer

Hans Briem

Kirstin Petersen

Benjamin Bader

Norbert Schmees

Nicolas Werbeck

Dennis Kirchhoff

Mareike Grees

Dirk Kosemund

Bernd Buchmann

Roland Neuhaus

Olaf Panknin

Detlef Stöckigt

Sandra Berndt

Mark Trautwein

Philipp Beckhove

Jörg Willuda

Rafael Carretero

Christina Kober

Manfred Husemann

Jeffrey Stuart Mowat

Christian Lechner

Gabriele Leder

Hans-Henning Böhm

Ulrike Roehn

Corinna Link

Ulf Boemer

Thi Thanh Uyen Nguyen

Lars Wortmann

Robin Michael Meier

Nuria Aiguabella Font

Katrin Nowak-reppel

Detlef Stoeckigt

Anders Roland Friberg

Ulrich Rosentreter

The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.

Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminoquinolones as DGKalpha inhibitors for immune activation

The present invention covers aminothiazole compounds of general formula (I), in which R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminothiazoles as DGKzeta inhibitors for immune activation

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R, R, R, R, R, Rand Rare as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control. 

Substituted pyrrolopyridine-derivatives

Growing community of inventors

Heidelberg, Germany

Rienk Offringa